What's in Akesobio Australia Pty Ltd's pipeline?

Akesobio Australia Pty Ltd has 3 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 2 in Phase 1.

Which companies overlap with Akesobio Australia Pty Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/akesobio-australia-pty-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Akesobio Australia Pty Ltd — Portfolio Competitive Intelligence Brief

Akesobio Australia Pty Ltd pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
AK120	AK120	phase 3	Bispecific T cell engager	CD3 and tumor-associated antigen (specific target not publicly disclosed)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Akesobio Australia Pty Ltd:

Cite this brief

Drug Landscape (2026). Akesobio Australia Pty Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/akesobio-australia-pty-ltd. Accessed 2026-05-16.